 Shares of Cocrystal Pharma Inc. plunged 28.3 in active premarket trading, after the biotechnology company announced a 40 million common stock offering. The company announced the offering Tuesdays closing bell, after the stock rocketed 72.6 on Tuesday after the announcement that progress was made in the development of the companys antiviral drug candidates targeting coronaviruses including those that cause COVID-19. 